DOCSLIB.ORG

Effect of Human Fibroblast Interferon on the Antiviral Activity of Mammalian Cells Treated with Bleomycin, Vincristine, Or Mitomycin C1

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Effect of Human Fibroblast Interferon on the Antiviral Activity of Mammalian Cells Treated with Bleomycin, Vincristine, Or Mitomycin C1 [CANCER RESEARCH 43, 5462-5466. November 1983] Effect of Human Fibroblast Interferon on the Antiviral Activity of Mammalian Cells Treated with Bleomycin, Vincristine, or Mitomycin C1 Robert J. Suhadolnik,2 Yosuke Sawada,3 Maryann B. Flick, Nancy L. Reichenbach, and Joseph D. Mosca3 Department of Biochemistry, Temple University School of Medicine, Philadelphia, Pennsylvania 19140 ABSTRACT protein kinase (2,9,28,34,36). In addition to the use of interferon in the treatment of cancer (1, 11, 12, 29, 34), combination Bleomycin, vincristine, or mitomycin C, when added to HeLa chemotherapy of interferon and methotrexate, c/s-platinum diam- cells simultaneously with human fibroblast interferon (IFN-0), minedichloride, cyclophosphamide, or 1,3-bis(/i-chloroethyl)-1- caused a decrease in cell density and inhibited DMA synthesis nitrosourea on either tumor cells in culture or in leukemic mice compared with HeLa cells treated with IFN-/3 alone. However, has been reported (5, 7, 10, 25). Furthermore, Stolfi ef al. (37) the IFN-0-induced antiviral processes were unaffected by the reported recently that the administration of mouse interferon to presence of these drugs as determined by in vitro enzyme assays mice following the administration of 5-fluorouracil protected the and the development of the antiviral state in the intact HeLa cell. mice from mortality. Because it is possible to selectively inhibit HeLa cells treated with IFN-/Õalone or with IFN-/3 in combination proliferation of tumor cells with chemotherapeutic drugs, we with bleomycin, vincristine, or mitomycin C were able to induce reasoned that the ability of the normal cell to maintain the antiviral the double-stranded RNA-dependent adenosine triphos- phate:2',5'-oligoadenylic acid adenyltransferase (EC 2.2.2.-) and state might be adversely affected by such drugs and that the antiproliferative action of interferons might affect the activity of the double-stranded RNA-dependent protein kinase. Further drugs used in the treatment of human cancers. To provide a firm more, the antiviral state as measured by the reduction of plaque- foundation for the use of interferons in combination with antineo- forming units after infection of treated cells (with IFN-0 alone or plastic drugs in the treatment of cancer, we have determined the with IFN-0 plus drugs) with vesicular stomatitis virus was not effect of combination treatments of IFN-/3 added simultaneously affected. These results indicate that, under these experimental with either bleomycin, mitomycin C, or vincristine on cell metab conditions, the double-stranded RNA-dependent adenosine tri- phosphate^',5'-oligoadenylic acid adenyltransferase and pro olism, the potentiation of interferon action, and induction of the antiviral state. tein kinase can be induced by IFN-,3 in cells treated with bleo mycin, vincristine, or mitomycin C. These cells also develop the MATERIALS AND METHODS antiviral state. These experiments could provide a basis for a careful examination of the effects of interferon on the develop Interferon and Other Chemicals. IFN-/J (8 x 105 lU/mg protein) was ment of the antiviral state when testing potentially active anti- obtained from Dr. C. Baglioni, State University of New York at Albany, neoplastic agents. The possibility that IFN-/3 potentiates the and Dr. D. S. Rabson, Chief, Cancer Biology and Drug Program, NIH; cytotoxic effects of bleomycin and mitomycin C on HeLa cells is sheep-specific antiserum to IFN-/5 and sheep mock antiserum were also discussed. obtained from Dr. S. Cunningham, National Institute of Allergy and Infectious Diseases. Bleomycin and mitomycin C were from Sigma Chemical Co. (St. Louis, Mo.); vincristine was from Eli Lilly and Co. INTRODUCTION (Indianapolis, Ind.); P. chrysogenum dsRNA was from Dr. R. J. Douthart, Interferons are a family of proteins produced in mammalian Eli Lilly and Co.; and elF-2«was from Dr. W. C. Merrick, Case Western Reserve University. Noncovalently associated polyriboinosinic-polyribo- cells in response to viral infection or other stimuli (2, 9, 28, 34, cytidylic acid, noncovalently associated polyriboinosinic:polyribocytidylic 36). There is evidence for potent, multiple effects of interferons acid:agarose, and 2',5'-oligoadenylate core dimer and core trimer were in mammalian cells. For example, interferon inhibits virus infec from P-L Biochemicals (Milwaukee, Wis.). [Me(/iy/-3H]thymidine (6.7 Ci/ tion, cell division, and cell functions; augments natural killer cell mmol) and [8-3H]ATP (22 Ci/mmol) were obtained from New England activity; modulates immune responses; and has been reported Nuclear (Boston, Mass.); [a-32P]ATP (410 Ci/mmol) and [-y-^PJATP (410 to have antitumor action (2, 3, 9,11-14, 34, 36). The anticellular Ci/mmol) were obtained from Amersham/Searle Corp. (Arlington Heights, effect of interferon was recognized as distinct from its antiviral III.). VSV and tritiated T-4 DNA were gifts from Dr. Earl E. Henderson, activity by Paucker ef al. (27) in 1962. The antiviral response of Temple University School of Medicine. interferons in mammalian cells appears to be mediated by the Cell Culture. HeLa S-3 cells (Flow Laboratories, McLean, Va.) were induction of the dsRNA4-dependent 2',5'-An synthetase and a maintained in suspension culture in Joklik's modified MEM, pH 7.3, supplemented with 5% fetal calf serum and 5% calf serum (Grand Island 1Supported in part by BiomédicalResearch Support Grant S07 RR05417 from Biological Co., Grand Island, N. Y.) (generation time, 20 to 22 hr). Vero the Division of Research Resources, NIH. cells (Flow Laboratories) were grown in monolayer culture in Eagle's 2 Recipient of NIH Research Grant GM-26134. To whom requests for reprints MEM, pH 7.0, supplemented with 6% fetal calf serum. Cells were counted should be addressed. 3 Recipient of partial support from USPHS Training Grant 5-T32 AM-07162. in a hemacytometer, and cell viability was determined by trypan blue 4The abbreviations used are: dsRNA, double-stranded RNA; 2',5'-A„synthe exclusion. Twenty-four hr prior to treatment, the cells are resuspended tase, ATP:2',5'-oligoadenylic acid adenyltransferase (EC 2.2.2.-; 2' ,5'-A„,oligomer in fresh medium. Immediately before treatment, the cells are diluted for of adenylic acid with 2',5'-phosphodiester linkages and a triphosphate at the 5'- 2 x 106 cells/ml in the same medium and aliquoted to separate flasks end); IFN-(i, human fibroblast interferon; elF-2«, «subunit of eukaryotic initiation for treatment. Concentrations are given in the tables and figures. factor 2; VSV, vesicular stomatitis virus; MEM, minimal essential medium; SDS, 2',5'-An Synthetase Assay. 2'.5'-A, synthetase was assayed by 2 sodium dodecyl sulfate; PFU, plaque-forming units. Received May 6. 1983; accepted July 29, 1983. methods. Treated HeLa cells were lysed, and the synthetase was as- 5462 CANCER RESEARCH VOL. 43 Downloaded from cancerres.aacrjournals.org on October 1, 2021. © 1983 American Association for Cancer Research. IFN-ßandAntineoplastic Agents in HeLa Cells sayed as described (21). Protein in these lysates was determined ac cording to the method of Lowry ef al. (18). HeLa cells treated as described under interferon neutralization assay were lysed, and the 2',5'-A„syn- thetase was assayed as described (20, 33). Protein in these lysates was IO determined according to the method of Bradford (4). Incorporation of [3H]Thymidine into Acid-insoluble Material. Two- O mi aliquots of cell culture were centrifuged (1400 x g, 1 min), and the cell pellets were washed once with 1 ml of Spinner's buffer. Acid-insoluble radioactivity was collected on Whatman GF/A filters and washed with 3 ml of 5% trichloroacetic acid and 5 ml of 95% ethanol. Filters were dried under an infrared lamp, and radioactivity was determined in a Beckman A Model LS-100C liquid scintillation spectrometer using Scintillation Fluid I Z 949 (New England Nuclear). Alkaline Sucrose Gradient Centrif ugation. Lysis of cells and alkaline sucrose gradients of DNA were performed as described by Krokan ef al. (15). Gradients were fractionated dropwise from the bottom (20 drops/ fraction); 3 ml of 10% trichloroacetic acid, 0°, plus 200 /ig of bovine serum albumin were added to each fraction. The trichloroacetic acid precipitate was collected on Whatman GF/A filters and washed with 3 ml of 5% trichloroacetic acid and 5 ml of 95% ethanol. The filters were < s dried under an IR lamp, and the radioactivity was determined. Protein Kinase Assay. The interferon-induced dsRNA-dependent pro O 20 40 60 246 004 0.12 tein kinase was assayed in ribosomal fractions prepared by centrifugation Bleomycin Mitomycin C Vincristine of homogenized lysates at 225,000 x g for 1 hr at 4°as described (17). The reaction was terminated by the addition of 10 n\ of H2O and 5 M!of buffer containing 50 mM Tris-HCI (pH 7.4), 0.8% SDS, and 2.5% 2- Chart 1. Effect of increasing concentrations of bleomycin, mitomycin C, and vincristine on cell density, incorporation of [3H]thymidine into DNA, and the induction mercaptoethanol. Each sample was heated 5 min in a steam bath of 2',5'-A„synthetase in IFN-tf-treated cells. HeLa cells in the log phase of growth followed by the addition of 5 n\ of 2% bromophenol blue in glycerol. The (2 x 10s cells/ml, 50 ml) were treated simultaneously with IFN-fi (100 units/ml) and samples were applied to SDS slab gels (0.1 % SDS: 10% acrylamide:0.3% either bleomycin, mitomycin C. or vincristine at the concentrations indicated. Twenty bisacrylamide, 1 mm thick) and electrophoresed as described (17). Gels hr later, cell density, [3H]thymidine incorporation into DNA, and 2' ,5'-A„synthetase activity were determined. A, cell density; B, [3H]thymidine incorporated into DNA; were stained with 0.05% Coomassie blue in 10% acetic acid:33% 2- C, 2',5'Ai synthetase activity (100% represents the values from cells treated with propanol overnight at 25°,destained (soaking the gel once in 7% acetic IFN-o alone); 1, bleomycin; 2, mitomycin C; 3, vincristine (100% of 2',5'-A„ acid:30% 2-propanol and 3 to 4 times thereafter in 7% acetic acid), dried, synthetase represents 45,000 dpm) (C).
Load more

Recommended publications
  • Testicular Cancer Treatment Regimens
    Testicular Cancer Treatment Regimens Clinical Trials: The NCCN recommends cancer patient participation in clinical trials as the gold standard for treatment. Cancer therapy selection, dosing, administration, and the management of related adverse events can be a complex process that should be handled by an experienced healthcare team. Clinicians must choose and verify treatment options based on the individual patient; drug dose modifications and supportive care interventions should be administered accordingly. The cancer treatment regimens below may include both U.S. Food and Drug Administration-approved and unapproved indications/regimens. These regimens are only provided to supplement the latest treatment strategies. These Guidelines are a work in progress that may be refined as often as new significant data becomes available. The National Comprehensive Cancer Network Guidelines® are a consensus statement of its authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult any NCCN Guidelines® is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient’s care or treatment. The NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way. Note: All recommendations are category 2A unless otherwise indicated. uPrimary Chemotherapy for Germ Cell Tumors1 REGIMEN DOSING Preferred Regimens BEP (Bleomycin + Etoposide + Days 1-5: Cisplatin 20mg/m2 IV over 60 minutes dailya Cisplatin)2,a,b Days 1-5: Etoposide 100mg/m2 IV over 60 minutes daily Days 1,8,15 OR Days 2,9,16: Bleomycin 30 units IV over 10 minutes daily.
    [Show full text]
  • Prednisolone-Rituximab-Vincristine (Rpacebom)
    Chemotherapy Protocol LYMPHOMA BLEOMYCIN-CYCLOPHOSPHAMIDE-DOXORUBICIN-ETOPOSIDE-METHOTREXATE- PREDNISOLONE-RITUXIMAB-VINCRISTINE (RPACEBOM) Regimen Lymphoma – RPACEBOM-Bleomycin-Cyclophosphamide-Doxorubicin-Etoposide- Methotrexate-Prednisolone-Rituximab-Vincristine Indication CD20 Positive Non Hodgkin’s Lymphoma Toxicity Drug Adverse Effect Bleomycin Pulmonary toxicity, rigors, skin pigmentation, nail changes Cyclophosphamide Dysuria, haemorrragic cystitis (rare), taste disturbances Doxorubicin Cardiotoxicity, urinary discolouration (red) Etoposide Hypotension on rapid infusion, alopecia, hyperbilirubinaemia Methotrexate Stomatitis, conjunctivitis, renal toxicity Weight gain, GI disturbances, hyperglycaemia, CNS disturbances, Prednisolone cushingoid changes, glucose intolerance Severe cytokine release syndrome, increased incidence of Rituxumab infective complications, progressive multifocal leukoencephalopathy Vincristine Peripheral neuropathy, constipation, jaw pain The adverse effects listed are not exhaustive. Please refer to the relevant Summary of Product Characteristics for full details. Version 1.2 (Jan 2015) Page 1 of 16 Lymphoma- RPACEBOM-Bleomycin-Cyclophospham-Doxorubicin-Etoposide-Methotrexate-Prednisolone-Rituximab-Vincristine Monitoring Drugs FBC, LFTs and U&Es prior to day one and fifteen Albumin prior to each cycle Regular blood glucose monitoring Check hepatitis B status before starting treatment with rituximab The presence of a third fluid compartment e.g. ascites or renal failure may delay the clearance of methotrexate
    [Show full text]
  • Cisplatin, Methotrexate and Bleomycin for Advanced Recurrent Or
    : Ope gy n A lo c ro c d e s n s A Yumura et al., Andrology (Los Angel) 2017, 6:2 Andrology-Open Access DOI: 10.4172/2167-0250.1000194 ISSN: 2167-0250 Research Article Open Access Cisplatin, Methotrexate and Bleomycin for Advanced Recurrent or Metastatic Penile Squamous Cell Carcinoma Yumura Y*, Kasuga J, Kawahara T, Miyoshi Y, Hattori Y, Teranishi J, Takamoto D, Mochizuki T and Uemura H Department of Urology and Renal Transplantation, Yokohama City University Medical Center, Japan *Corresponding author: Yasushi Yumura, Departments of Urology and Renal Transplantation, Yokohama City University Medical Center, Japan, Tel: +81452615656; Fax: +81452531962; E-mail: [email protected] Received date: December 11, 2017; Accepted date: December 15, 2017; Published date: December 22, 2017 Copyright: © 2017 Yumura Y, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Abstract Objective: This study aimed to evaluate the efficacy and toxicity of cisplatin, methotrexate, and bleomycin (CMB) chemotherapy in patients with advanced, recurrent, or metastatic penile squamous cell carcinoma (PSCC). Methods: The CMB regimen was administered to 12 patients with advanced (n=7), recurrent (n=4), or metastatic (n=1) PSCC. Patients received a total of 21 cycles of CMB between 2002 and 2009, and were retrospectively reviewed for treatment efficacy and toxicity of the drugs. The mean patient age was 61 (61.0 ± 8.7) years. Patients received 20.0 mg/m2 of cisplatin intravenously on days 2-6; 200.0 mg/m2 of methotrexate intravenously on days 1, 15 and 22; and 10.0 mg/m2 of bleomycin as a bolus on days 2-6.
    [Show full text]
  • Chemotherapy of Ovarian Cancer Directed by the Human Tumor Stem Cell Assay
    UC Irvine UC Irvine Previously Published Works Title Chemotherapy of ovarian cancer directed by the human tumor stem cell assay. Permalink https://escholarship.org/uc/item/7fz6p03p Journal Cancer chemotherapy and pharmacology, 6(3) ISSN 0344-5704 Authors Alberts, D S Chen, H S Salmon, S E et al. Publication Date 1981 Peer reviewed eScholarship.org Powered by the California Digital Library University of California Cancer Chemother Pharmacol (1981) 6: 279-285 ancer hernotherapy and harmacology O Springer-Verlag 1981 Chemotherapy of Ovarian Cancer Directed by the Human Tumor Stem Cell Assay David S. ~lberts',H. S. George Chen1,2, Sydney E. salmon1, Earl A. surwit1>3, Laurie young1, Thomas E. ~oon',and Frank L. Meyskens, .Trl, and Co-investigators from the Arizona-New Mexico Tumor Cloning Group" The Cancer Center, College of Medicine, Department of Chemical Engineering, College of Mines, Department of Obstetrics and Gynecology, College of Medicine, University of Arizona, Tucson, AZ 85724, USA Summary. The human tumor stem cell assay ovarian cancer of epithelial type [6, 22, 261. In the (HTSCA) has been used to study the in vitro sensitivity past chemotherapy has been selected on an empirical rates of anticancer drugs used in the treatment of 115 basis, with as many as three or more agents being patients with previously untreated and relapsing combined for the treatment of newly diagnosed ovarian cancer. The data from these studies have patients with stages 111 and IV disease [9, 25, 271. identified patterns of cross resistance and residual When patients relapse following therapy with multi- sensitivity between these agents, and have allowed the ple-drug regimens the response rate to single agents is prospective selection of single agents possessing in in the range of 0-25% [12,21,28].
    [Show full text]
  • Cancer Drug Costs for a Month of Treatment at Initial Food and Drug
    Cancer drug costs for a month of treatment at initial Food and Drug Administration approval Year of FDA Monthly Cost Monthly cost Generic name Brand name(s) approval (actual $'s) (2014 $'s) vinblastine Velban 1965 $78 $586 thioguanine, 6-TG Thioguanine Tabloid 1966 $17 $124 hydroxyurea Hydrea 1967 $14 $99 cytarabine Cytosar-U, Tarabine PFS 1969 $13 $84 procarbazine Matulane 1969 $2 $13 testolactone Teslac 1969 $179 $1,158 mitotane Lysodren 1970 $134 $816 plicamycin Mithracin 1970 $50 $305 mitomycin C Mutamycin 1974 $5 $23 dacarbazine DTIC-Dome 1975 $29 $128 lomustine CeeNU 1976 $10 $42 carmustine BiCNU, BCNU 1977 $33 $129 tamoxifen citrate Nolvadex 1977 $44 $170 cisplatin Platinol 1978 $125 $454 estramustine Emcyt 1981 $420 $1,094 streptozocin Zanosar 1982 $61 $150 etoposide, VP-16 Vepesid 1983 $181 $430 interferon alfa 2a Roferon A 1986 $742 $1,603 daunorubicin, daunomycin Cerubidine 1987 $533 $1,111 doxorubicin Adriamycin 1987 $521 $1,086 mitoxantrone Novantrone 1987 $477 $994 ifosfamide IFEX 1988 $1,667 $3,336 flutamide Eulexin 1989 $213 $406 altretamine Hexalen 1990 $341 $618 idarubicin Idamycin 1990 $227 $411 levamisole Ergamisol 1990 $105 $191 carboplatin Paraplatin 1991 $860 $1,495 fludarabine phosphate Fludara 1991 $662 $1,151 pamidronate Aredia 1991 $507 $881 pentostatin Nipent 1991 $1,767 $3,071 aldesleukin Proleukin 1992 $13,503 $22,784 melphalan Alkeran 1992 $35 $59 cladribine Leustatin, 2-CdA 1993 $764 $1,252 asparaginase Elspar 1994 $694 $1,109 paclitaxel Taxol 1994 $2,614 $4,176 pegaspargase Oncaspar 1994 $3,006 $4,802
    [Show full text]
  • A Phase II Study of Docetaxel in Patients with Metastatic Squamous
    British Journal of Cancer (1999) 81(3), 457–462 © 1999 Cancer Research Campaign Article no. bjoc.1999.0715 A phase II study of docetaxel in patients with metastatic squamous cell carcinoma of the head and neck C Couteau1, N Chouaki1, S Leyvraz3, D Oulid-Aissa2, A Lebecq2, C Domenge1, V Groult2, S Bordessoule3, F Janot1, M De Forni1 and J-P Armand1 1Institut Gustave Roussy, Department of Medecine, 39 rue Camille Desmoulins, 94805 Villejuif, France; 2Rhone Poulenc Rorer, Antony, France; 3Centre Pluridisciplinaire d’Oncologie, University Hospital, Lausanne, Switzerland Summary This study was designed to evaluate the activity, safety and tolerance of docetaxel (D) in a selected population with metastatic squamous cell carcinoma of the head and neck (SCCHN). Twenty-four patients with no prior palliative therapy were enrolled and received D 100 mg m–2 by 1 h of infusion, every 3 weeks. All but two patients had been evaluated for efficacy on lung metastatic sites. No prophylactic administration of anti-emetics or growth factors was given. A pharmacokinetic study was performed in 22 patients. Twenty-one patients were assessable for response and 24 for toxicity. One hundred and four cycles were administered with a median of 4.5 (range 1–9) per patient. The median cumulative dose was 449 mg m–2. Partial responses were achieved in five patients with a median duration of 18.7 weeks (range 13.1–50.3). The overall response rate was 20.8% with a median duration of 11.0 weeks (range 2.4–52.6). The most frequent side-effect was neutropenia (79.2% grade IV) but with a short duration (median 4 days) and no febrile neutropenia.
    [Show full text]
  • Bleomycin, Etoposide and Cisplatin (BEP) Therapy
    NCCP Chemotherapy Regimen Bleomycin, Etoposide and CISplatin (BEP) Therapy INDICATIONS FOR USE: Regimen Reimbursement INDICATION ICD10 Code Status Adjuvant treatment of high risk (vascular invasion C62 00300a Hospital carcinoma) stage 1 nonseminoma germ cell tumour Metastatic germ cell tumours of the testis C62 00300b Hospital Advanced stage or metastatic germ cell tumours C56 00300c Hospital (dysgerminoma) of the ovaries Extra-gonadal germ cell tumours C56/C62 00300d Hospital TREATMENT: The starting dose of the drugs detailed below may be adjusted downward by the prescribing clinician, using their independent medical judgement, to consider each patients individual clinical circumstances. Treatment with etoposide and CISplatin is administered on days 1-5, and treatment with bleomycin is administered on days 1, 8 and 15 of a 21 day cycle. For good risk patients - 3 cycles are administered, For intermediate to poor risk patients - 4 cycles are administered Facilities to treat anaphylaxis MUST be present when the chemotherapy is administered. Admin Day Drug Dose Route Diluent & Rate Order 1 1, 8 and 15 Bleomycin a30,000 International Units IV Bolus (30mg) or IMb 2 1-5 Etoposide 100mg/m2 IV infusion 1000ml 0.9% NaCl over 60 minutesc 3 1-5 CISplatin 20mg/m2 IV infusion 1000ml 0.9% NaCl over 1 hour (Pre hydration therapy required) d Bleomycin dosing may be referred to in international units (IU) or in mg. 1,000 international units = 1mg aThe total cumulative dose of bleomycin should NOT exceed 400,000 international units (400mg). The risk of pulmonary toxicity increases beyond a cumulative dose of 300,000 international units (300mg).
    [Show full text]
  • Antitumor Antibiotics: Bleomycin, Enediynes, and Mitomycin
    Chem. Rev. 2005, 105, 739−758 739 Antitumor Antibiotics: Bleomycin, Enediynes, and Mitomycin Ute Galm,† Martin H. Hager,† Steven G. Van Lanen,† Jianhua Ju,† Jon S. Thorson,*,† and Ben Shen*,†,‡ Division of Pharmaceutical Sciences and Department of Chemistry, University of Wisconsin, Madison, Wisconsin 53705 Received July 19, 2004 Contents their clinical utilities and shortcomings, a comparison of resistance mechanisms within producing organ- 1. Introduction 739 isms to those predominant among tumor cells reveals 2. Bleomycin 739 remarkable potential for continued development of 2.1. Discovery and Biological Activities 739 these essential anticancer agents. 2.2. Clinical Resistance 740 2.2.1. Bleomycin Hydrolase 741 2. Bleomycin 2.2.2. Enhanced DNA Repair 742 2.2.3. Bleomycin Binding Protein 742 2.1. Discovery and Biological Activities 2.2.4. Other Mechanisms 743 The bleomycins (BLMs), such as bleomycinic acid 2.3. Resistance by the Producing Organisms 743 (1), BLM A2 (2), or BLM B2 (3), are a family of 2.3.1. Bleomycin N-Acetyltranferase (BlmB) 743 glycopeptide-derived antibiotics originally isolated 2.3.2. Bleomycin Binding Protein (BlmA) 743 from several Streptomyces species.2,3 Several struc- 2.3.3. Transport Proteins 744 ture variations of the naturally occurring BLMs have 3. EnediynessNine-Membered Enediyne Core 744 been identified from fermentation broths, primarily Subfamily differing at the C-terminus of the glycopeptide. The 3.1. Discovery and Biological Activities 745 BLM structure was revised in 19784 and confirmed 3.2. Resistance by the Producing Organisms 746 by total synthesis in 1982.5,6 Structurally and bio- 3.2.1.
    [Show full text]
  • (BEP 5 Day) Regimen • Germ Cell – Bleomycin-Cisplatin-Etoposid
    Chemotherapy Protocol GERM CELL BLEOMYCIN-CISPLATIN-ETOPOSIDE (BEP 5 Day) Regimen • Germ Cell – Bleomycin-Cisplatin-Etoposide (5 day BEP) Indication • In patients 40 years and below with; - metastatic non-seminomatous germ cell tumours - metastatic seminoma where radiotherapy is not appropriate - renal impairment or a poor performance status Toxicity Drug Adverse Effect Bleomycin Pulmonary toxicity, rigors, skin pigmentation, nail changes Cisplatin Neuropathy, nephrotoxicity, ototoxicity Etoposide Hypotension on rapid infusion, alopecia, hyperbilirubineamia The adverse effects listed are not exhaustive. Please refer to the relevant Summary of Product Characteristics for full details. Monitoring Drugs • FBC, LFTs and U&Es on day one of the cycle • AFP, HCG prior to day one of the cycle • Chest x-ray • Consider pulmonary function tests before starting therapy. These should be repeated if respiratory symptoms develop during treatment, particularly a drop in oxygen saturation on exercise. Bleomycin should be stopped until the results of such investigations are known. Dose Modifications The dose modifications listed are for haematological, liver and renal function and drug specific toxicities only. Dose adjustments may be necessary for other toxicities as well. In principle all dose reductions due to adverse drug reactions should not be re-escalated in subsequent cycles without consultant approval. It is also a general rule for chemotherapy that if a third dose reduction is necessary treatment should be stopped. Version 1 (July 2017) Page 1 of 9 Germ Cell–Bleomycin-Cisplatin-Etoposide (5 day BEP) Patients are being treated with curative intent therefore dose modifications and delays should be kept to a minimum. Please discuss all dose reductions / delays with the relevant consultant before prescribing.
    [Show full text]
  • Cancer Drug Costs for a Month of Treatment at Initial Food
    Cancer drug costs for a month of treatment at initial Food and Drug Administration approval Year of FDA Monthly Cost Monthly cost (2013 Generic name Brand name(s) approval (actual $'s) $'s) Vinblastine Velban 1965 $78 $575 Thioguanine, 6-TG Thioguanine Tabloid 1966 $17 $122 Hydroxyurea Hydrea 1967 $14 $97 Cytarabine Cytosar-U, Tarabine PFS 1969 $13 $82 Procarbazine Matulane 1969 $2 $13 Testolactone Teslac 1969 $179 $1,136 Mitotane Lysodren 1970 $134 $801 Plicamycin Mithracin 1970 $50 $299 Mitomycin C Mutamycin 1974 $5 $22 Dacarbazine DTIC-Dome 1975 $29 $125 Lomustine CeeNU 1976 $10 $41 Carmustine BiCNU, BCNU 1977 $33 $127 Tamoxifen citrate Nolvadex 1977 $44 $167 Cisplatin Platinol 1978 $125 $445 Estramustine Emcyt 1981 $420 $1,074 Streptozocin Zanosar 1982 $61 $147 Etoposide, VP-16 Vepesid 1983 $181 $422 Interferon alfa 2a Roferon A 1986 $742 $1,573 Daunorubicin, Daunomycin Cerubidine 1987 $533 $1,090 Doxorubicin Adriamycin 1987 $521 $1,066 Mitoxantrone Novantrone 1987 $477 $976 Ifosfamide IFEX 1988 $1,667 $3,274 Flutamide Eulexin 1989 $213 $399 Altretamine Hexalen 1990 $341 $606 Idarubicin Idamycin 1990 $227 $404 Levamisole Ergamisol 1990 $105 $187 Carboplatin Paraplatin 1991 $860 $1,467 Fludarabine phosphate Fludara 1991 $662 $1,129 Pamidronate Aredia 1991 $507 $865 Pentostatin Nipent 1991 $1,767 $3,015 Aldesleukin Proleukin 1992 $13,503 $22,364 Melphalan Alkeran 1992 $35 $58 Cladribine Leustatin, 2-CdA 1993 $764 $1,229 Asparaginase Elspar 1994 $694 $1,088 Paclitaxel Taxol 1994 $2,614 $4,099 Pegaspargase Oncaspar 1994 $3,006 $4,713
    [Show full text]
  • Gangrene of the Fingertips After Bleomycin and Methotrexate
    Gangrene of the Fingertips After Bleomycin and Methotrexate Osvaldo Correia, MD, Porto, Portugal Fernando Ribas, MD, Porto, Portugal Rosa Azevedo, MD, Porto, Portugal Helena Rodrigues, MD, Porto, Portugal Luis Delgado, MD, PhD, Porto, Portugal The increased use of cytostatic drugs, which are sometimes used in combination chemotherapy, may result in new and unusual cutaneous side effects. We describe a 57-year-old man with acral erythrocyanosis progressing to acute digital ischemia and gangrene that developed after com- bined chemotherapy (bleomycin and methotrex- ate) used to treat a metastatic squamous cell carcinoma of the hypopharynx. A leukocytoclastic vasculitis was found in both the acute phase and in the amputated fingertips. This supports the well- reported potential of bleomycin to trigger acral vascular toxicity. leomycin is an antibiotic with antiviral, anti- bacterial, and antitumor activity isolated from B Streptomyces verticillus. It has often been used to FIGURE 1. Acral erythrocyanosis with ischemic ulcera- treat squamous cell carcinoma of the head and neck, tions of the fingertips. either alone or in combination, usually with methotrexate.1,2 Bleomycin is useful in combination chemotherapy because it rarely is myelosuppressive such as alopecia, mucositis, macular erythema, epi- and its most significant side effects are lung fibrosis dermal necrosis, and acral erythema. Bone marrow and skin changes. Cutaneous side effects include suppression, interstitial pneumonitis unrelated to cu- stomatitis; alopecia; erythema; hyperpigmentation; mulative dosage, and hepatitis with long-term ad- vascular toxicity, including Raynaud’s phenomenon ministration are serious systemic side effects.4,5 with and without ischemic ulcerations; and sclerosis- We report an unusual case of erythrocyanosis pro- like changes that may progress to gangrene.2,3 gressing to acute ischemia and gangrene after combi- Methotrexate is an inhibitor of dihydrofolate reduc- nation chemotherapy with bleomycin and tase and can induce adverse reactions in the skin, methotrexate.
    [Show full text]
  • The Effect of 5-Aminolevulinic Acid Based Photodynamic Therapy and Photochemical Internalization of Bleomycin on the F98 Rat Glioma Cell Line
    UNLV Retrospective Theses & Dissertations 1-1-2008 The effect of 5-aminolevulinic acid based photodynamic therapy and photochemical internalization of bleomycin on the F98 rat glioma cell line Khishigzaya Kharkhuu University of Nevada, Las Vegas Follow this and additional works at: https://digitalscholarship.unlv.edu/rtds Repository Citation Kharkhuu, Khishigzaya, "The effect of 5-aminolevulinic acid based photodynamic therapy and photochemical internalization of bleomycin on the F98 rat glioma cell line" (2008). UNLV Retrospective Theses & Dissertations. 2296. http://dx.doi.org/10.25669/7km5-6xyc This Thesis is protected by copyright and/or related rights. It has been brought to you by Digital Scholarship@UNLV with permission from the rights-holder(s). You are free to use this Thesis in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from the rights-holder(s) directly, unless additional rights are indicated by a Creative Commons license in the record and/ or on the work itself. This Thesis has been accepted for inclusion in UNLV Retrospective Theses & Dissertations by an authorized administrator of Digital Scholarship@UNLV. For more information, please contact [email protected]. THE EFFECT OF 5-AMlNOLEVULlNlC ACID BASED PHOTODYNAMIC THERAPY AND PHOTOCHEMICAL INTERNALIZATION OF BLEOMYCIN ON THE F98 RAT GLIOMA CELL LINE by Khishigzaya Kharkhuu Bachelor of Science Moscow Power Engineering Institute 2003 A thesis submitted in partial fulfillment of the requirement for the Master of Science Degree in Health Physics Department of Health Physics School of Allied Health Sciences Division of Health Sciences Graduate College University of Nevada, Las Vegas May 2008 UMI Number: 1456345 INFORMATION TO USERS The quality of this reproduction is dependent upon the quality of the copy submitted.
    [Show full text]